

## Eyetelligence Assure Suite

AI Software for Eye Disease Screening + Cardiovascular Disease Risk Assessment

# Harness the power of AI to see into the future of patient health

Eyetelligence Assure screens full-colour retinal fundus images for features of glaucoma, referable diabetic retinopathy and referable neovascular age-related macular degeneration, with the Assure+ software adding cardiovascular disease risk assessment.

Trained by a team of sub-specialist ophthalmologists, the software uses a database of over 2,500,000 retinal scans to accurately provide early detection of indicated diseases with proven accuracy.


At Optain, we see a world where early detection of chronic disease through AI-empowered health assessments is universally accessible.

Our AI sets new benchmarks in affordable disease screening tools, while its evidence-based reporting empowers clinicians to make informed decisions with speed, accuracy, and confidence.

For more information  
please scan the QR code



info@eyevinci.nl






# AI-enabled software for eye disease screening

Trained on over 2,500,000 retinal images for an accuracy of 95%<sup>1</sup>.

Eyetelligence Assure software suite has been trained by a team of sub-specialist ophthalmologists to analyse images using a database of over 2,500,000 retinal scans to accurately provide early detection of major eye diseases with proven accuracy.

Manage serious diseases with peace of mind.

Empower your practice with instant reports to support clinical decisions, treatment, and referrals. Share clinical evidence with patients for their peace of mind. Make fast and affordable evidence-based decisions for quality coordinated care.



**TGA and CE mark Class 1 Medical Device.**  
 Eyetelligence Assure software is classified as a Class 1 medical device, with Australian TGA listing and European CE Mark, conforming to the performance and safety standards in over 30 countries across the EU and Australasia<sup>2</sup>.


1. AI model has a 95% accuracy rate based on AUC study data, see our website for more details.  
 2. For country-specific regulatory information, please contact your local Optain representative.

# How Eyetelligence Assure works

1. Capture retinal images of the patient. The camera centres and triggers fully automatically releases.



2. The images will appear in the software interface. Choose the images requiring analysis.




3. Receive analysis within seconds for features of common eye diseases.



4. Check the results section for a list of the day's patients and results.



5. View and download the clinical or patient reports branded with your clinic logo.



# Discover the benefits



Make decisions based on accurate analysis

Detect the features of glaucoma, neovascular age-related macular degeneration, and diabetic retinopathy with an accuracy of 95%<sup>2</sup>.



Boost the power of your fundus camera

Seamless integrations empower clinicians with expert analysis based on digital fundus images to help support and make more informed choices.



Non-invasive early detection to minimise risk

Eyetelligence Assure makes it easy to understand the patient's level of risk so that you can begin to manage their condition. All it requires is taking a retinal photo of the patient's eyes.



Greater patient certainty, compliance and understanding

Helps patients better understand clinical assessments through clear and easy-to-understand patient reports and supporting information.




# Add the power of cardiovascular disease risk assessment with Eyetelligence Assure+

CVD kills 1 in 4 Australians<sup>3</sup>.  
We see a better future.

Eyetelligence Assure+ adds another level to our revolutionary eye disease assessment capability. Clinically validated AI algorithms analyse the microvasculature within retinal images to generate heatmaps revealing patterns indicative of cardiovascular risk, resulting in non-invasive, rapid, and accurate detection for timely intervention.

Eyetelligence Assure+ identifies the low, moderate, and high-risk potential for cardiovascular disease with an accuracy of 90%<sup>4</sup>.

Optometrists seeing features of heart disease can refer patients for appropriate tests or treatment. Meanwhile, GPs detecting early stages of eye disease may refer patients for comprehensive eye examinations or interventions. Either way, this represents positive life-impacting patient outcomes and added business value.



*“AI won’t replace clinicians, but clinicians who use AI will replace those who don’t.”*

Dr. Bertalan Meskó  
The Medical Futurist

Eyevinci B.V. - Nijverheidsweg 15, 2102 LJ Heemstede  
Mobile: +31 (0) 88 6008700, www.eyevinci.nl

Regulatory Disclaimer

Optain AI-enabled Eyetelligence Assure+ software is classified as a Class 1 medical device, with Australian TGA listing and European CE Mark, conforming to the performance and safety standards in over 30 countries across the EU and Australasia. For country-specific regulatory information, please contact your local Optain representative.

Eyetelligence Assure+ software is intended for the assessment of the retinal vascular system and to screen for microvascular health issues of the body, based on full colour fundus photos that are generated from a fundus camera. The Eyetelligence system outcomes are intended to be subsequently verified and certified by a qualified medical/eye care professional who will make a clinical decision based on a range of inputs not limited to Eyetelligence outcomes.

References

- www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- Lin, Z., Shi, D., Zhang, D., Shang, X., He, M., & Ge, Z. (2022, September). Camera Adaptation for Fundus-Image-Based CVD Risk Estimation. In International Conference on Medical Image Computing and Computer-Assisted Intervention (pp. 593-603). Cham: Springer Nature Switzerland. (https://research.monash.edu/en/publications/camera-adaptation-forfundus-image-based-cvd-risk-estimation)